Here we share our own experience using GLP-1 RA and dual GIP/GLP-1 RA therapy in genetically confirmed MODY, with a focus on glycaemic control, weight, and the potential to reduce or stop sulfonylureas and insulin. This evidence concerns the gene INS and MODY.